• Cyclo (-RGDfC): Precision αvβ3 Integrin Targeting Peptide...

  2026-01-29

  Cyclo (-RGDfC), a cyclic RGD peptide, offers high-affinity and specificity for the αvβ3 integrin receptor. This integrin αvβ3 receptor targeting peptide is a benchmark tool for cancer research and angiogenesis studies. Its validated performance, solubility, and workflow integration make it a preferred choice for high-throughput and mechanistic investigations.

• Parathyroid hormone (1-34) (human): Redefining Kidney Dis...

  2026-01-29

  Explore how Parathyroid hormone (1-34) (human) is transforming calcium homeostasis and bone metabolism research. This article uniquely examines its mechanistic role as a parathyroid hormone 1 receptor agonist within next-generation kidney assembloid models and osteoporosis studies.

• 2-Deoxy-D-glucose: Advanced Modulation of Tumor and Immun...

  2026-01-28

  Explore the multifaceted role of 2-Deoxy-D-glucose (2-DG), a potent glycolysis inhibitor, in cancer metabolism, immune reprogramming, and antiviral research. This article uniquely integrates metabolic checkpoint science with translational applications, offering a deeper analysis of 2-DG's impact on tumor microenvironment and immunometabolic pathways.

• Pioglitazone: PPARγ Agonist for Metabolic & Inflammatory ...

  2026-01-28

  Pioglitazone is a selective PPARγ agonist widely used for type 2 diabetes mellitus research and studies of inflammatory process modulation. Recent evidence supports its utility in regulating macrophage polarization and oxidative stress reduction. APExBIO's Pioglitazone (B2117) enables reproducible workflows for insulin resistance mechanism studies.

• 2'3'-cGAMP (Sodium Salt): Decoding NAD Depletion, Mitocho...

  2026-01-27

  Explore how 2'3'-cGAMP (sodium salt) enables advanced investigation of STING-mediated innate immune responses triggered by NAD depletion and mitochondrial DNA leakage. This article uniquely integrates core biochemical mechanisms with emerging translational applications in immunotherapy and antiviral research.

• BIIE 0246: Unraveling Y2R Antagonism for Adipose-Neural A...

  2026-01-27

  Explore the multifaceted applications of BIIE 0246, a potent neuropeptide Y Y2 receptor antagonist, in dissecting the adipose-neural axis and its role in cardiac arrhythmias. Gain unique insights into advanced mechanistic studies and translational neuroscience using this selective tool.

• 2'3'-cGAMP (Sodium Salt): Precision STING Agonist for Imm...

  2026-01-26

  2'3'-cGAMP (sodium salt) is revolutionizing STING-mediated innate immune response studies, offering unmatched specificity and potency for dissecting the cGAS-STING pathway. Its water solubility, high STING affinity, and proven performance in experimental workflows make it indispensable for cancer immunotherapy and antiviral research.

• Gastrin I (human): Precision Tool for CCK2 Receptor Pathw...

  2026-01-26

  Gastrin I (human), a validated endogenous peptide, is a key regulator in gastric acid secretion pathway research. Its high-purity specification and defined CCK2 receptor agonism make it essential for gastrointestinal physiology studies, especially in advanced in vitro and organoid models. This article clarifies its mechanistic scope and benchmarks its utility in translational GI disorder research.

• 2'3'-cGAMP (sodium salt): Precision Tool for STING Pathwa...

  2026-01-25

  2'3'-cGAMP (sodium salt) unlocks robust and reproducible activation of the cGAS-STING pathway, enabling advanced studies in type I interferon induction, cancer immunotherapy, and antiviral innate immunity. APExBIO’s validated STING agonist sets the standard for assay consistency and translational research acceleration.

• Pioglitazone: A PPARγ Agonist Powering Metabolic Disease ...

  2026-01-24

  Pioglitazone is redefining experimental paradigms in metabolic, inflammatory, and neurodegenerative research by modulating the PPARγ pathway with high specificity. Discover how this peroxisome proliferator-activated receptor gamma activator streamlines workflows, enables advanced disease modeling, and overcomes common technical pitfalls for robust, reproducible results.

• Cyclo (-RGDfC): Precision αvβ3 Integrin Binding in Cancer...

  2026-01-23

  Cyclo (-RGDfC) stands out as a robust αvβ3 integrin binding cyclic peptide, unlocking new frontiers in tumor targeting, angiogenesis research, and integrin-mediated assay development. Its high specificity, DMSO solubility, and validated reproducibility empower researchers to dissect integrin signaling pathways and optimize targeted delivery strategies in cancer research. Discover how this cyclic RGD peptide streamlines experimental workflows and addresses bench-to-bedside challenges.

• BIIE 0246 and the Neuropeptide Y Y2 Receptor: Strategic I...

  2026-01-23

  This thought-leadership article delivers a mechanistic and strategic roadmap for translational researchers investigating the neuropeptide Y (NPY) signaling pathway and the adipose-neural axis. By leveraging BIIE 0246—a highly selective NPY Y2 receptor antagonist—researchers can dissect presynaptic inhibitory mechanisms, feeding behavior modulation, and the emerging role of Y2R in cardiac arrhythmogenesis. Integrating recent evidence from Fan et al. (2024) and APExBIO’s product intelligence, we explore experimental best practices, competitive landscape, and visionary translational strategies, while highlighting how this discussion advances beyond conventional product narratives.

• 2'3'-cGAMP (Sodium Salt): Benchmark Cyclic GMP-AMP for ST...

  2026-01-22

  2'3'-cGAMP (sodium salt) is a potent, endogenous STING agonist enabling precise dissection of the cGAS-STING pathway in innate immune signaling. This article details its molecular action, experimental benchmarks, and optimal use in immunotherapy and antiviral research.

• Cyclo (-RGDfC): Unveiling New Frontiers in Integrin αvβ3 ...

  2026-01-22

  Discover how Cyclo (-RGDfC), a cutting-edge αvβ3 integrin binding cyclic peptide, enables precise spatial control in advanced biomaterials and programmable cell systems. This in-depth analysis reveals scientific strategies for next-generation angiogenesis research and tumor targeting.

• BIIE 0246: Unlocking Y2 Receptor Antagonism for Advanced ...

  2026-01-21

  Discover how BIIE 0246, a potent neuropeptide Y Y2 receptor antagonist, enables precise dissection of neuropeptide Y signaling in both neuroscience and cardiac research. This in-depth exploration highlights unique mechanistic insights and translational applications not covered elsewhere.

16019 records 2/1068 page Previous Next 12345 下5页 Last page